Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas-Reference-Cited by-同舟云学术

Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas

Published:2022-02-07 Issue:4 Volume:39 Page:1596-1610
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Cerdà Serdà Paula,Terés Raúl,Sebio Ana,Bagué Silvia,Orellana Ruth,Moreno María E.,Riba Mireia,López-Pousa Antonio

Funder

PharmaMar

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02051-2.pdf

Reference30 articles.

1. Gajdos C, Elias A. Trabectedin: safety and efficacy in the treatment of advanced sarcoma. Clin Med Insights Oncol. 2011;5:35–43.

2. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70:200–29.

3. National Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: soft tissue including heart cancer. https://seer.cancer.gov/statfacts/html/soft.html. Accessed Aug 2021.

4. Savina M, Le Cesne A, Blay JY, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15:78.

5. European Medicines Agengy. Yondelis. https://www.ema.europa.eu/en/documents/product-information/yondelis-epar-product-information_en.pdf. Accessed Aug 2021.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy;Cell Communication and Signaling;2024-01-25

2. Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis;Frontiers in Oncology;2022-12-08

3. Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial;Cancers;2022-10-25

4. Trabectedin;Reactions Weekly;2022-07